Main Study Findings

The latest study findings will be shared as they become available: 

• Pre-existing antibody reactivity to SARS-CoV-2 is common in adults. Read the study:
  A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
   
• Extending mRNA SARS-CoV-2 vaccine dosing intervals is particularly advantageous against the Delta variant. Read the study:
  Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
   
• Most children with inflammatory bowel disease ​receiving anti-inflammatory anti-TNF medications respond well to two doses of the Pfizer COVID-19 mRNA vaccine. Read the study:
  Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy

Where can I learn more information about the study? 

If you have questions after reading the study information, please email abcovid@bcchr.ca.